

Supplementary Information

Synthesis and assessment of 4-aminotetrahydroquinazoline derivatives as tick-borne encephalitis virus reproduction inhibitors

Kseniya N. Sedenkova,^{a,b} Evgenia V. Dueva,^{a,c} Elena B. Averina,*^{a,b} Yuri K. Grishin,^a Dmitry I. Osolodkin,^{a,c} Liubov I. Kozlovskaya,^c Vladimir A. Palyulin,^{a,b} Evgenii N. Savelyev,^d Boris S. Orlinson,^d Ivan A. Novakov,^d Gennady M. Butov,^d Tamara S. Kuznetsova,^a Galina G. Karganova *^{c,e} and Nikolay S. Zefirov^{a,b}

^a Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia. Fax: +7-495-939-02-90; E-mail: elaver@org.chem.msu.ru

^b Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Moscow Region 142432, Russia.


^c Chumakov Institute of Poliomyelitis and Viral Encephalitides, Moscow 142782, Russia. E-mail: karganova@bk.ru.

^d Volgograd State Technical University, Volgograd, 400005, Russia.

^e Department of Biology, Lomonosov Moscow State University, Moscow 119991, Russia.

Synthesis of 4-aminotetrahydroquinazoline derivatives 7a–ab	S2
NMR spectra of compounds 7a–ab	S9
Time-of-addition assay results for the chosen compounds.....	S47

General procedure for the synthesis of the compounds 7a–ab



The mixture of tetrahydroquinazoline derivative **3a–c**, **5a** (0.5 mmol), corresponding amine (0.5 mmol) and DIPEA (129 mg, 1.0 mmol) in ethanol (1 mL) was stirred for 24 h. The solvent was evaporated in vacuo, the product was isolated via column chromatography (SiO₂).

N-Butyl-2-methyl-5,6,7,8-tetrahydroquinazoline-4-amine 1-oxide (**7a**).

Obtained as colorless oil (42 mg, 36%); *R_f* 0.2 (CHCl₃); δ_{H} (400 MHz, CDCl₃): 0.96 (3H, t, $^3J_{\text{HH}}$ 7.3, CH₃, Bu), 1.32–1.46 (2H, m, CH₂, Bu), 1.53–1.63 (2H, m, CH₂, Bu), 1.75–1.87 (4H, m, 2CH₂, cy-Hex), 2.30 (2H, br t, $^3J_{\text{HH}}$ 5.9, CH₂, cy-Hex), 2.63 (3H, s, CH₃), 2.91 (2H, br t, $^3J_{\text{HH}}$ 5.9, CH₂, cy-Hex), 3.48 (2H, dt, $^3J_{\text{HH}}$ 5.9, $^3J_{\text{HH}}$ 7.1, CH₂NH), 4.47 (1H, br s, NH); δ_{C} (101 MHz, CDCl₃): 13.8 (CH₃, Bu), 20.1 (CH₂), 20.2 (CH₃), 20.8 (CH₂), 21.0 (CH₂), 22.1 (CH₂), 24.6 (CH₂), 31.6 (CH₂), 40.9 (CH₂NH), 111.6 (C4a), 152.0 (C), 153.1 (C), 154.8 (C); HRMS (ESI⁺, *m/z*): calc. for C₁₃H₂₁N₃O [M+H] 236.1757, found 236.1760.

N-Benzyl-2-methyl-5,6,7,8-tetrahydroquinazoline-4-amine 1-oxide (**7b**).

Obtained as yellow oil (64 mg, 50%); *R_f* 0.1 (petroleum ether:ethyl acetate:MeOH 3:1:1); δ_{H} (400 MHz, CDCl₃): 1.75–1.86 (4H, m, 2CH₂, cy-Hex), 2.32 (2H, t, $^3J_{\text{HH}}$ 5.6, CH₂, cy-Hex), 2.67 (3H, s, CH₃), 2.94 (2H, t, $^3J_{\text{HH}}$ 5.7, CH₂, cy-Hex), 4.70 (2H, d, $^3J_{\text{HH}}$ 5.4, CH₂NH), 4.98 (1H, br s, NH), 7.29–7.40 (5H, m, Ph); δ_{C} (101 MHz, CDCl₃): 20.2 (CH₃), 20.7 (CH₂, cy-Hex), 20.9 (CH₂, cy-Hex), 22.1 (CH₂, cy-Hex), 24.6 (CH₂, cy-Hex), 45.4 (CH₂NH), 111.7 (C4a), 127.7 (2CH, Ph), 127.9 (CH, Ph), 128.7 (2CH, Ph), 138.3 (C, Ph), 152.6 (C, Pyr), 154.0 (C, Pyr), 155.8 (C, Pyr); HRMS (ESI⁺, *m/z*): calc. for C₁₆H₁₉N₃O [M+H] 270.1601, found 270.1601.

N-Benzyl-2-*tert*-butyl-5,6,7,8-tetrahydroquinazoline-4-amine 1-oxide (**7c**).

Obtained as yellowish solid (101 mg, 68%); mp 144–147°C (from CHCl₃, with decomposition); *R_f* 0.1 (petroleum ether:ethyl acetate:MeOH 3:1:0.1); δ_{H} (400 MHz, CDCl₃): 1.51 (9H, s, 3CH₃), 1.72–1.84 (4H, m, 2CH₂, cy-Hex), 2.34 (2H, br t, $^3J_{\text{HH}}$ 5.6, CH₂, cy-Hex), 2.88 (2H, br t, $^3J_{\text{HH}}$ 5.6, CH₂, cy-Hex), 4.70 (2H, d, $^3J_{\text{HH}}$ 5.6, CH₂NH), 5.16 (1H, br s, NH), 7.25–7.36 (5H, m, 5CH, Ph); δ_{C} (101 MHz, CDCl₃): 20.8 (CH₂, cy-Hex), 21.2 (CH₂, cy-Hex), 22.2 (CH₂, cy-Hex), 24.6 (CH₂, cy-Hex), 26.9 (3CH₃), 38.7 (C, *t*-Bu), 45.2 (CH₂Ph), 111.9 (C4a, Pyr), 127.4 (CH, Ph), 127.7 (2CH, Ph), 128.6 (2CH, Ph), 139.0 (C, Ph), 150.7 (C4, Pyr), 155.1 (C8a, Pyr), 161.2 (C2, Pyr); HRMS (ESI⁺, *m/z*): calc. for C₁₉H₂₅N₃O [M+H] 312.2070, found 312.2078.

N-(4-Methoxybenzyl)-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (**7d**).

Obtained as yellowish solid (60 mg, 40%); mp 189–191°C (from CHCl₃, with decomposition); *R_f* 0.3 (petroleum ether:ethyl acetate:MeOH 3:1:1). Found: C, 68.45; H, 7.1; N, 14.1. Calc. for C₁₇H₂₁N₃O₂: C, 68.2, H, 7.1, N, 14.0%. δ_{H} (400 MHz, CDCl₃): 1.68–1.81 (4H, m, 2CH₂, cy-Hex), 2.27 (2H, t, $^3J_{\text{HH}}$ 5.8, CH₂, cy-Hex), 2.61 (3H, s, CH₃), 2.85 (2H, t, $^3J_{\text{HH}}$ 5.6, CH₂, cy-Hex), 3.76 (3H, s, CH₃O), 4.55 (2H, d, $^3J_{\text{HH}}$ 5.3, CH₂NH), 4.95 (1H, br s, NH), 6.80–6.85 (2H, m, Ar), 7.19–7.23 (2H, m, Ar); δ_{C} (101 MHz, CDCl₃): 20.2 (CH₃), 20.8 (CH₂, cy-Hex), 21.0 (CH₂, cy-Hex), 22.1 (CH₂, cy-Hex), 24.6 (CH₂, cy-Hex), 44.8 (CH₂NH), 55.3 (CH₃O), 111.8 (C4a), 114.0

(2CH, Ar), 129.2 (2CH, Ar), 130.7 (C, Ar), 151.3 (C, Pyr), 153.4 (C, Pyr), 154.7 (C, Pyr), 159.0 (C, Ar).

2-Methoxy-5-[(2-methyl-1-oxido-5,6,7,8-tetrahydroquinazolin-4-yl)amino]methylphenol (7e).

Obtained as yellow oil (45 mg, 42%); *R_f* 0.5 (MeOH); δ_{H} (400 MHz, CDCl₃): 1.61–1.73 (4H, m, 2CH₂, cy-Hex), 2.40–2.48 (2H, CH₂, cy-Hex), 2.61 (3H, s, CH₃), 2.79–2.85 (2H, CH₂, cy-Hex), 3.79 (3H, s, CH₃O), 4.61 (2H, d, ³*J*_{HH} 5.9, CH₂NH), 6.78 (1H, d, ³*J*_{HH} 8.2, Ar), 6.83 (1H, dd, ³*J*_{HH} 8.2, ⁴*J*_{HH} 1.6, Ar), 7.01 (1H, d, ⁴*J*_{HH} 1.6, 1H, Ar), 8.04 (1H, br s, NH), 9.06 (1H, br s, OH); δ_{C} (101 MHz, CDCl₃): 18.8 (CH₃), 20.3 (CH₂, cy-Hex), 20.6 (CH₂, cy-Hex), 22.6 (CH₂, cy-Hex), 24.4 (CH₂, cy-Hex), 44.8 (CH₂NH), 56.0 (CH₃O), 111.8 (CH, Ar), 113.4 (C4a), 114.3 (CH, Ar), 121.3 (CH, Ar), 129.5 (C, Ar), 145.2 (C, Pyr), 146.7 (C, Pyr), 152.5 (C, Pyr), 157.2 (C, Ar), 158.2 (C, Ar); HRMS (ESI⁺, *m/z*): calc. for C₁₇H₂₁N₃O₃ [M+H] 316.1656, found 316.1667.

2-Methyl-4-morpholin-4-yl-5,6,7,8-tetrahydroquinazoline 1-oxide (7f).

Obtained as colorless oil (106 mg, 85%); *R_f* 0.8 (CHCl₃:MeOH 10:1); δ_{H} (400 MHz, CDCl₃): 1.63–1.72 (2H, m, CH₂, cy-Hex), 1.83–1.92 (2H, m, CH₂, cy-Hex), 2.53 (2H, t, ³*J*_{HH} 5.9, CH₂, cy-Hex), 2.64 (3H, s, CH₃), 2.94 (2H, t, ³*J*_{HH} 5.9, CH₂, cy-Hex), 3.28–3.34 (4H, m, 2CH₂), 3.76–3.81 (4H, m, 2CH₂); δ_{C} (101 MHz, CDCl₃): 20.0 (CH₃), 21.2 (CH₂), 21.6 (CH₂), 25.5 (CH₂), 26.3 (CH₂), 48.9 (2CH₂N), 66.7 (2CH₂O), 118.7 (C4a), 154.6 (C), 155.2 (C), 155.7 (C); HRMS (ESI⁺, *m/z*): calc. for C₁₃H₁₉N₃O₂ [M+H] 250.1550, found 250.1549.

2-Methyl-4-morpholin-4-yl-5,6,7,8-tetrahydroquinazoline (7g).

Obtained as colorless oil (76 mg, 65%); *R_f* 0.3 (petroleum ether:ethyl acetate:MeOH 3:1:0.5); δ_{H} (400 MHz, CDCl₃): 1.66–1.76 (2H, m, CH₂, cy-Hex), 1.81–1.90 (2H, m, CH₂, cy-Hex), 2.50 (2H, t, ³*J*_{HH} 6.1, CH₂, cy-Hex), 2.52 (3H, s, CH₃), 2.81 (2H, t, ³*J*_{HH} 6.7, CH₂, cy-Hex), 3.35–3.40 (4H, m, 2CH₂), 3.77–3.83 (4H, m, 2CH₂); δ_{C} (101 MHz, CDCl₃): 22.3 (CH₂, cy-Hex), 22.9 (CH₂, cy-Hex), 25.3 (CH₃), 26.4 (CH₂, cy-Hex), 31.6 (CH₂, cy-Hex), 48.5 (2CH₂), 66.8 (2CH₂), 115.2 (C4a), 163.5 (C), 164.3 (C), 165.1 (C); HRMS (ESI⁺, *m/z*): calc. for C₁₃H₁₉N₃O [M+H] 234.1601, found 234.1601.

4-Morpholin-4-yl-2-*tert*-butyl-5,6,7,8-tetrahydroquinazoline 1-oxide (7h).

Obtained as yellowish solid (63 mg, 43%); mp 68–70°C (from CHCl₃), *R_f* 0.1 (petroleum ether:ethyl acetate:MeOH 3:1:0.3); δ_{H} (400 MHz, CDCl₃): 1.47 (9H, s, 3CH₃), 1.60–1.68 (2H, m, CH₂, cy-Hex), 1.79–1.88 (2H, m, 2CH₂, cy-Hex), 2.50 (2H, br t, ³*J*_{HH} 5.9, CH₂, cy-Hex), 2.87 (2H, br t, ³*J*_{HH} 6.6, CH₂, cy-Hex), 3.24–3.28 (4H, m, 2CH₂N), 3.74–3.78 (4H, m, 2CH₂O); δ_{C} (101 MHz, CDCl₃): 21.51 (CH₂, cy-Hex), 21.52 (CH₂, cy-Hex), 25.4 (CH₂, cy-Hex), 26.1 (CH₂, cy-Hex), 26.6 (3CH₃), 38.7 (C, *t*-Bu), 48.9 (2CH₂N), 66.72 (2CH₂O), 118.8 (C4a, Pyr), 153.5 (C4, Pyr), 157.1 (C8a, Pyr), 160.3 (C2, Pyr). HRMS (ESI⁺, *m/z*): calc. for C₁₆H₂₅N₃O₂ [M+H] 292.2020, found 292.2022.

2-Methyl-4-piperazin-1-yl-5,6,7,8-tetrahydroquinazoline 1-oxide (7i).

Obtained as yellowish oil (112 mg, 90%); *R_f* 0.8 (CHCl₃:MeOH 10:1); δ_{H} (400 MHz, CDCl₃): 1.50–1.60 (2H, m, CH₂, cy-Hex), 1.71–1.80 (2H, m, CH₂, cy-Hex), 2.42 (2H, br t, ³*J*_{HH} 5.6, CH₂, cy-Hex), 2.50 (3H, s, CH₃), 2.78 (2H, br t, ³*J*_{HH} 5.9, CH₂, cy-Hex), 2.83–2.88 (4H, m, 2CH₂), 3.11–3.14 (4H, m, 2CH₂), 4.61 (1H, br s, NH); δ_{C} (101 MHz, CDCl₃): 19.8 (CH₂), 21.3 (CH₃),

21.6 (CH₂), 25.4 (CH₂), 26.1 (CH₂), 45.8 (2CH₂), 49.7 (2CH₂), 119.0 (C4a), 151.4 (C), 154.0 (C), 155.2 (2C); HRMS (ESI⁺, m/z): calc. for C₁₃H₂₀N₄O [M+H] 249.1710, found 249.1713.

2-Methyl-4-piperazin-1-yl-5,6,7,8-tetrahydroquinazoline (7j).

Obtained as hydrochloride, white solid (79 mg, 59%); δ_{H} (400 MHz, CD₃OD): 1.71–1.81 (2H, m, CH₂, cy-Hex), 1.87–1.96 (2H, m, CH₂, cy-Hex), 2.59 (3H, s, CH₃), 2.70 (2H, t, ³J_{HH} 5.6, CH₂, cy-Hex), 2.88 (2H, t, ³J_{HH} 6.4, CH₂, cy-Hex), 3.38–3.43 (4H, m, 2CH₂), 4.15–4.20 (4H, m, 2CH₂); δ_{C} (101 MHz, CD₃OD): 19.9 (CH₂), 20.1 (CH₃), 21.8 (CH₂), 26.3 (CH₂), 26.7 (CH₂), 43.0 (2CH₂), 44.4 (2CH₂), 114.3 (C4a), 155.4 (C), 158.1 (C), 164.1 (C); HRMS (ESI⁺, m/z): calc. for C₁₃H₂₀N₄ [M+H] 233.1761, found: 233.1753.

4-Piperazin-1-yl-2-tert-butyl-5,6,7,8-tetrahydroquinazoline 1-oxide (7k).

Obtained as white solid (46 mg, 32%); mp 69–71°C (from CHCl₃); R_f 0.2 (MeOH); δ_{H} (400 MHz, CDCl₃/CD₃OD): 1.42 (9H, s, 3CH₃), 1.55–1.64 (2H, m, CH₂, cy-Hex), 1.76–1.84 (2H, m, 2CH₂, cy-Hex), 2.46 (2H, br t, ³J_{HH} 5.8, CH₂, cy-Hex), 2.80 (2H, br t, ³J_{HH} 6.5, CH₂, cy-Hex), 2.86–2.92 (4H, m, 2CH₂), 3.25–3.30 (4H, m, 2CH₂); δ_{C} (101 MHz, CDCl₃/CD₃OD): 21.30 (CH₂, cy-Hex), 21.33 (CH₂, cy-Hex), 25.2 (CH₂, cy-Hex), 26.3 (CH₂, cy-Hex), 26.7 (3CH₃), 38.8 (C, *t*-Bu), 45.2 (2CH₂), 48.9 (2CH₂), 118.6 (C4a, Pyr), 155.0 (C4, Pyr), 157.2 (C8a, Pyr), 160.7 (C2, Pyr); HRMS (ESI⁺, m/z): calc. for C₁₆H₂₆N₄O [M+H] 291.2179, found: 291.2183.

2-Methyl-N-phenyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7l).

Obtained as colorless oil (61 mg, 48%); R_f 0.9 (CHCl₃:MeOH 10:1); δ_{H} (400 MHz, CDCl₃): 1.77–1.84 (4H, m, 4CH₂), 2.59 (2H, br t, ³J_{HH} 5.3, CH₂), 2.62 (3H, s, CH₃), 2.86–2.91 (2H, m, CH₂), 5.01 (1H, br s, NH), 7.14 (1H, t, ³J_{HH} 8.1, CH, Ph), 7.33 (2H, dd, ³J_{HH} 8.1, ³J_{HH} 8.1, 2CH, Ph), 7.61 (2H, d, ³J_{HH} 8.1, 2CH, Ph); δ_{C} (101 MHz, CDCl₃): 20.4 (CH₃), 20.47 (CH₂), 20.52 (CH₂), 22.8 (CH₂), 24.8 (CH₂), 114.2 (C4a, Pyr), 122.2 (2CH), 125.0 (CH), 128.9 (2CH), 137.5 (C, Ph), 152.9 (C, Pyr), 154.4 (C, Pyr), 156.5 (C, Pyr); HRMS (ESI⁺, m/z): calc. for C₁₅H₁₇N₃O [M+H] 256.1444, found 256.1446.

N-Phenyl-2-tert-butyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7m).

Obtained as yellowish oil (46 mg, 31%); R_f 0.6 (MeOH); δ_{H} (400 MHz, CDCl₃): 1.53 (9H, s, 3CH₃), 1.80–1.85 (4H, m, 2CH₂), 2.49–2.53 (2H, m, CH₂), 2.89–2.93 (2H, m, CH₂), 6.54 (1H, s, NH), 7.06 (1H, tt, ³J_{HH} 7.5, ⁴J_{HH} 0.9, CH, Ph), 7.28–7.34 (2H, m, 2CH, Ph), 7.57–7.62 (2H, m, 2CH, Ph); δ_{C} (101 MHz, CDCl₃): 20.8 (CH₂), 21.0 (CH₂), 22.5 (CH₂), 24.9 (CH₂), 27.0 (3CH₃), 39.2 (C, *t*-Bu), 113.4 (C4a, Pyr), 120.3 (2CH), 123.3 (CH), 128.8 (2CH), 138.7 (C, Ph), 148.2 (C4, Pyr), 156.3 (C8a, Pyr), 161.4 (C2, Pyr); HRMS (ESI⁺, m/z): calc. for C₁₈H₂₃N₃O [M+H] 298.1914, found 298.1913.

2-Methyl-N-(4-methylphenyl)-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7n).

Obtained as yellowish oil (20 mg, 15%); R_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:1); δ_{H} (400 MHz, CDCl₃): 1.80–1.86 (4H, m, 2CH₂), 2.31 (3H, s, CH₃, Ph), 2.45–2.51 (2H, m, CH₂), 2.62 (3H, s, CH₃, Pyr), 2.90–2.94 (2H, m, CH₂), 6.47 (1H, br s, NH), 7.12 (2H, d, ³J_{HH} 8.3, 2CH, Ph), 7.41 (2H, d, ³J_{HH} 8.3, 2CH, Ph); δ_{C} (101 MHz, CDCl₃): 12.0 (CH₃, Ar), 20.2 (CH₃, Pyr), 20.8 (CH₂), 20.9 (CH₂), 22.5 (CH₂), 24.8 (CH₂), 113.0 (C4a), 121.0 (2CH), 129.4 (2CH), 133.6 (C, Ar), 135.7 (C, Ar), 149.6 (C, Pyr), 154.6 (C, Pyr), 155.0 (C, Pyr); HRMS (ESI⁺, m/z): calc. for C₁₆H₁₉N₃O [M+H] 270.1601, found 270.1597.

2-[(2-Methyl-1-oxido-5,6,7,8-tetrahydroquinazolin-4-yl)amino]phenol (7o).

Obtained as yellowish oil (49 mg, 36%); *R*_f 0.5 (MeOH); δ_{H} (400 MHz, CDCl₃): 1.63–1.71 (4H, m, 2CH₂), 2.29–2.36 (2H, m, CH₂), 2.68 (3H, s, CH₃), 2.75–2.82 (2H, m, CH₂), 6.79–6.86 (2H, m, 2CH, Ph), 6.89 (1H, d, ³*J*_{HH} 4.0, Ph), 8.19 (1H, d, ³*J*_{HH} 7.8, CH, Ph); δ_{C} (101 MHz, CDCl₃): 20.3 (CH₃), 20.4 (CH₂), 20.5 (CH₂), 22.0 (CH₂), 24.6 (CH₂), 114.0 (C4a), 115.7 (CH), 119.7 (CH), 120.0 (CH), 123.9 (CH), 127.3 (CNH, Ph), 146.9 (COH, Ph), 150.8 (C, Pyr), 154.4 (C, Pyr), 155.6 (C, Pyr); HRMS (ESI⁺, *m/z*): calc. for C₁₅H₁₇N₃O₂ [M+H] 272.1394, found 272.1384.

***N*-(1-Adamantylmethyl)-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7p).**

Obtained as white solid (33 mg, 20%); mp 54–56°C (from CHCl₃); *R*_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.1); δ_{H} (400 MHz, CDCl₃): 1.49 (6H, br s, 3CH₂, Ad), 1.62 (3H, br d, ²*J*_{HH} ca. 12, 3CH₂, Ad), 1.70 (3H, br d, ²*J*_{HH} ca. 12, 3CH₂, Ad), 1.76–1.82 (4H, m, 2CH₂, cy-Hex), 1.96 (3H, br s, 3CH, Ad), 2.30 (2H, br t, ³*J*_{HH} 5.0, CH₂, cy-Hex), 2.59 (3H, s, CH₃), 2.89 (2H, br t, ³*J*_{HH} 5.2, CH₂, cy-Hex), 3.20 (2H, d, ³*J*_{HH} 5.9, CH₂NH), 4.54 (1H, br s, NH); δ_{C} (101 MHz, CDCl₃): 20.1 (CH₃), 20.9 (CH₂, cy-Hex), 21.0 (CH₂, cy-Hex), 22.1 (CH₂, cy-Hex), 24.5 (CH₂, cy-Hex), 28.2 (3CH, Ad), 34.0 (C, Ad), 36.9 (3CH₂, Ad), 40.5 (3CH₂, Ad), 52.3 (CH₂NH), 111.3 (C4a), 152.3 (C, Pyr), 153.1 (C, Pyr), 154.7 (C, Pyr); HRMS (ESI⁺, *m/z*): calc. for C₂₀H₂₉N₃O [M+H] 328.2383, found 328.2384.

***N*-(1-Adamantylmethyl)-2-*tert*-butyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7q).**

Obtained as white solid (48 mg, 26%); mp 160°C (with decomposition; from CHCl₃); *R*_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.5); δ_{H} (400 MHz, CDCl₃): 1.49 (6H, d, ³*J*_{HH} ca. 3, 3CH₂, Ad), 1.51 (9H, s, 3CH₃), 1.61 (3H, br d, ²*J*_{HH} ca. 12, 3CH₂, Ad), 1.70 (3H, br d, ²*J*_{HH} ca. 12, 3CH₂, Ad), 1.75–1.84 (4H, m, 2CH₂, cy-Hex), 1.96 (3H, br s, 3CH, Ad), 2.29 (2H, br t, ³*J*_{HH} 5.7, CH₂, cy-Hex), 2.88 (2H, br t, ³*J*_{HH} 5.4, CH₂, cy-Hex), 3.24 (2H, d, ³*J*_{HH} 6.2, CH₂NH), 4.46 (1H, br s, NH); δ_{C} (101 MHz, CDCl₃): 20.9 (CH₂, cy-Hex), 21.3 (CH₂, cy-Hex), 22.1 (CH₂, cy-Hex), 24.6 (CH₂, cy-Hex), 26.9 (3CH₃), 28.2 (3CH, Ad), 34.2 (C, Ad), 37.0 (3CH₂, Ad), 38.7 (C, *t*-Bu), 40.5 (3CH₂, Ad), 52.2 (CH₂NH), 111.2 (C4a), 151.1 (C4, Pyr), 154.8 (C8a, Pyr), 160.7 (C2, Pyr). HRMS (ESI⁺, *m/z*): calc. for C₂₃H₃₅N₃O [M+H] 370.2853, found 370.2849.

***N*-[1-(1-Adamantyl)ethyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7r).**

Obtained as yellowish oil (26 mg, 15%); *R*_f 0.2 (petroleum ether:EtOAc:MeOH 3:1:1); δ_{H} (400 MHz, CDCl₃): 1.07 (3H, d, ³*J*_{HH} 6.7, CH₃), 1.49 (3H, br d, ³*J*_{HH} ca. 12, 3CH₂, Ad), 1.56 (3H, br d, ²*J*_{HH} ca. 12, 3CH₂, Ad), 1.61 (3H, br d, ²*J*_{HH} ca. 12, 3CH₂, Ad), 1.71 (3H, br d, ²*J*_{HH} ca. 12, 3CH₂, Ad), 1.78–1.83 (4H, m, 2CH₂, cy-Hex), 1.95–1.99 (3H, m, 3CH, Ad), 2.25–2.29 (2H, m, CH₂, cy-Hex), 2.59 (3H, s, CH₃), 2.89 (2H, t, ³*J*_{HH} 5.8, CH₂, cy-Hex), 4.06 (1H, dq, ³*J*_{HH} 9.3, ³*J*_{HH} 6.7, CHNH), 4.41 (1H, d, ³*J*_{HH} 9.3, NH); δ_{C} (101 MHz, CDCl₃): 14.6 (CH₃), 20.2 (CH₃, Pyr), 20.8 (CH₂, cy-Hex), 20.9 (CH₂, cy-Hex), 22.0 (CH₂, cy-Hex), 24.5 (CH₂, cy-Hex), 28.3 (3CH, Ad), 36.2 (C, Ad), 37.0 (3CH₂, Ad), 38.6 (3CH₂, Ad), 54.0 (CHNH), 111.3 (C4a), 152.4 (C, Pyr), 153.2 (C, Pyr), 155.1 (C, Pyr); HRMS (ESI⁺, *m/z*): calc. for C₂₁H₃₁N₃O [M+H] calcd 342.2540, found 342.2526.

***N*-[2-(1-Adamantyl)ethyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7s).**

Obtained as white solid (61 mg, 36%); mp 227–229°C (from CHCl₃); *R*_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.3); δ_{H} (400 MHz, CDCl₃): 1.31–1.38 (2H, m, CH₂), 1.54 (6H, d, ³*J*_{HH} ca. 2, 3CH₂, Ad), 1.63 (3H, br d, ²*J*_{HH} ca. 12, 3CH₂, Ad), 1.71 (3H, br d, ²*J*_{HH} ca. 12, 3CH₂, Ad),

1.74–1.84 (4H, m, 2CH₂, cy-Hex), 1.92–1.98 (3H, m, 3CH, Ad), 2.26 (2H, t, ³J_{HH} 5.5, CH₂, cy-Hex), 2.62 (3H, s, CH₃), 2.89 (2H, t, ³J_{HH} 5.5, CH₂, cy-Hex), 3.44 (2H, dt, ³J_{HH} 10.7, ³J_{HH} 5.4, CH₂NH), 4.38 (1H, br s, NH); δ_C (101 MHz, CDCl₃): 20.2 (CH₃), 20.9 (CH₂, cy-Hex), 21.0 (CH₂, cy-Hex), 22.1 (CH₂, cy-Hex), 24.5 (CH₂, cy-Hex), 28.6 (3CH, Ad), 32.1 (C, Ad), 36.3 (CH₂NH), 37.0 (3CH₂, Ad), 42.5 (3CH₂, Ad), 44.0 (CH₂Ad), 111.5 (C4a), 151.8 (C, Pyr), 153.2 (C, Pyr), 155.0 (C, Pyr); HRMS (ESI⁺, m/z): calc. for C₂₁H₃₁N₃O [M+H] 342.2540, found 342.2538.

***N*-[2-(1-Adamantyl)ethyl]-2-ethyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7t).**

Obtained as yellowish oil (83 mg, 47%); R_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.3); δ_H (400 MHz, CDCl₃): 1.33 (3H, t, ³J_{HH} 7.5, CH₃), 1.36–1.41 (2H, m, CH₂), 1.57 (6H, d, ³J_{HH} ca. 2, 3CH₂, Ad), 1.66 (3H, br d, ²J_{HH} ca. 12, 3CH₂, Ad), 1.73 (3H, br d, ²J_{HH} ca. 12, 3CH₂, Ad), 1.77–1.87 (4H, m, 2CH₂, cy-Hex), 1.94–2.01 (3H, m, 3CH, Ad), 2.27–2.31 (2H, m, CH₂, cy-Hex), 2.92 (2H, t, ³J_{HH} 5.6, CH₂, cy-Hex), 3.07 (2H, q, ³J_{HH} 7.5, CH₂, Et), 3.52 (2H, dt, ³J_{HH} 10.5, ³J_{HH} 5.5, CH₂NH), 4.44–4.49 (1H, m, NH); δ_C (101 MHz, CDCl₃): 9.7 (CH₃), 20.9 (CH₂, cy-Hex), 21.1 (CH₂, cy-Hex), 22.0 (CH₂, cy-Hex), 24.5 (CH₂, cy-Hex), 25.3 (CH₂, Et), 28.6 (3CH, Ad), 32.1 (C, Ad), 36.2 (CH₂NH), 37.0 (3CH₂, Ad), 42.5 (3CH₂, Ad), 44.1 (CH₂Ad), 111.0 (C4a), 151.7 (C, Pyr), 153.1 (C, Pyr), 158.1 (C, Pyr); HRMS (ESI⁺, m/z): calc. for C₂₂H₃₃N₃O [M+H] 356.2696, found 356.2690.

***N*-[2-(1-Adamantyl)ethyl]-2-*tert*-butyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7u).**

Obtained as white solid (65 mg, 34%); mp 145–147°C (from CHCl₃, with decomposition); R_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.3); δ_H (400 MHz, CDCl₃): 1.29–1.36 (2H, m, CH₂Ad), 1.50 (15H, br s, 3CH₂, Ad + 3CH₃), 1.60 (3H, br d, ²J_{HH} ca. 12, 3CH₂, Ad), 1.68 (3H, br d, ²J_{HH} ca. 12, 3CH₂, Ad), 1.72–1.79 (4H, m, 2CH₂, cy-Hex), 1.90–1.94 (3H, m, 3CH, Ad), 2.22–2.26 (2H, m, CH₂, cy-Hex), 2.83–2.87 (2H, m, CH₂, cy-Hex), 3.46 (2H, dt, ³J_{HH} 10.8, ³J_{HH} 5.5, CH₂NH), 4.55 (1H, br.s, NH); δ_C (101 MHz, CDCl₃): 20.8 (CH₂, cy-Hex), 21.3 (CH₂, cy-Hex), 22.1 (CH₂, cy-Hex), 24.6 (CH₂, cy-Hex), 27.0 (3CH₃), 28.6 (3CH, Ad), 32.0 (C, Ad), 36.2 (CH₂NH), 37.0 (3CH₂, Ad), 38.7 (C, *t*-Bu), 42.5 (3CH₂, Ad), 44.1 (CH₂), 111.6 (C4a), 151.1 (C4, Pyr), 154.8 (C8a, Pyr), 161.1 (C2, Pyr). HRMS (ESI⁺, m/z): calc. for C₂₄H₃₇N₃O [M+H] 384.3009, found 384.3005.

***N*-[2-(2-Adamantyl)ethyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7v).**

Obtained as yellowish oil (111 mg, 65%); R_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.1); δ_H (400 MHz, CDCl₃): 1.48–1.90 (21H, m, 15H, Ad + 4H, 2CH₂, cy-Hex + 2H, CH₂), 2.30 (2H, br t, ³J_{HH} 5.6, CH₂, cy-Hex), 2.59 (3H, s, CH₃), 2.85 (2H, br t, ³J_{HH} 5.5, CH₂, cy-Hex), 3.39–3.51 (2H, m, CH₂NH), 4.90 (1H, br s, NH); δ_C (101 MHz, CDCl₃): 20.2 (CH₃), 20.8 (CH₂, cy-Hex), 20.9 (CH₂, cy-Hex), 22.1 (CH₂, cy-Hex), 24.5 (CH₂, cy-Hex), 28.0 (CH, Ad), 28.1 (CH, Ad), 31.6 (2CH₂, Ad), 31.9 (2CH, Ad), 32.5 (CH₂), 38.3 (CH₂), 39.1 (2CH₂, Ad), 39.9 (CH₂), 42.1 (CH, Ad), 111.9 (C4a), 152.8 (C, Pyr), 153.0 (C, Pyr), 155.3 (C, Pyr); HRMS (ESI⁺, m/z): calc. for C₂₁H₃₁N₃O [M+H] 342.2540, found 342.2537.

***N*-[2-(2-Adamantyl)ethyl]-2-*tert*-butyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7w).**

Obtained as white solid (119 mg, 62%); mp 217–219°C (from CHCl₃, with decomposition); R_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.3); δ_H (400 MHz, CDCl₃): 1.44–1.49 (2H, m, CH₂Ad), 1.49 (9H, s, 3CH₃), 1.63–1.72 (9H, m, Ad), 1.73–1.77 (4H, m, 2CH₂, cy-Hex), 1.77–1.86 (6H, m, Ad), 2.25 (2H, t, ³J_{HH} 5.2 Hz, CH₂, cy-Hex), 2.85 (2H, t, ³J_{HH} 5.5, CH₂, cy-Hex), 3.40–3.47

(2H, m, CH_2NH), 4.59 (1H, br s, NH); δ_C (101 MHz, $CDCl_3$): 20.9 (CH_2 , cy-Hex), 21.3 (CH_2 , cy-Hex), 22.1 (CH_2 , cy-Hex), 24.6 (CH_2 , cy-Hex), 26.8 (3 CH_3), 27.9 (CH, Ad), 28.1 (CH, Ad), 31.7 (2 CH_2 , Ad), 31.9 (2CH, Ad), 32.8 (CH_2), 38.2 (CH_2), 38.6 (C, *t*-Bu), 39.1 (2 CH_2 , Ad), 39.9 (CH_2), 42.2 (CH, Ad), 111.6 (C4a), 150.8 (C4, Pyr), 154.8 (C8a, Pyr), 160.9 (C2, Pyr); HRMS (ESI⁺, m/z): calc. for $C_{24}H_{37}N_3O$ [M+H] 384.3009, found 384.3005.

***N*-[2-(1-Adamantyl)oxyethyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7x).**

Obtained as yellowish oil (41 mg, 23%); R_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.3); δ_H (400 MHz, $CDCl_3$): 1.57 (3H, br d, $^2J_{HH}$ ca. 12, 3 CH_2 , Ad), 1.63 (3H, br d, $^2J_{HH}$ ca. 12, 3 CH_2 , Ad), 1.70 (6H, d, $^3J_{HH}$ ca. 2, 3 CH_2 , Ad), 1.73–1.83 (4H, m, 2 CH_2 , cy-Hex), 2.12 (3H, br s, 3CH, Ad), 2.28 (2H, br t, $^3J_{HH}$ 5.6, CH_2 , cy-Hex), 2.59 (3H, s, CH_3), 2.88 (2H, br t, $^3J_{HH}$ 5.8, CH_2 , cy-Hex), 3.53–3.60 (4H, m, CH_2O , CH_2NH), 4.99 (1H, br s, NH); δ_C (101 MHz, $CDCl_3$): 20.1 (CH_3), 20.9 (CH_2 , cy-Hex), 21.0 (CH_2 , cy-Hex), 22.0 (CH_2 , cy-Hex), 24.5 (CH_2 , cy-Hex), 30.4 (3CH, Ad), 36.3 (3 CH_2 , Ad), 41.5 (CH_2NH), 41.6 (3 CH_2 , Ad), 58.4 (CH_2O), 72.4 (C, Ad), 111.9 (C4a), 151.6 (C, Pyr), 153.3 (C, Pyr), 154.7 (C, Pyr); HRMS (ESI⁺, m/z): calc. for $C_{21}H_{31}N_3O_2$ [M+H] 358.2489, found 358.2485.

***N*-[1-Adamantyl(phenyl)methyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7y).**

Obtained as yellowish oil (103 mg, 51%); R_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.3); δ_H (400 MHz, $CDCl_3$): 1.46 (3H, br d, $^2J_{HH}$ ca. 12, 3 CH_2 , Ad), 1.53–1.60 (3H, m, 3 CH_2 , Ad), 1.65–1.70 (6H, m, 3 CH_2 , Ad), 1.79–1.85 (4H, m, 2 CH_2 , cy-Hex), 1.95–1.99 (3H, m, 3CH, Ad), 2.36–2.44 (2H, m, CH_2 , cy-Hex), 2.50 (3H, s, CH_3), 2.83–2.89 (2H, m, CH_2 , cy-Hex), 4.89 (1H, d, $^3J_{HH}$ 8.5, $CHNH$), 5.10 (1H, br d, $^3J_{HH}$ 8.5, NH), 7.16–7.19 (2H, m, 2CH, Ph), 7.20–7.30 (3H, m, 3CH, Ph); δ_C (101 MHz, $CDCl_3$): 20.1 (CH_3), 20.9 (CH_2 , cy-Hex), 21.0 (CH_2 , cy-Hex), 22.1 (CH_2 , cy-Hex), 24.5 (CH_2 , cy-Hex), 28.3 (3CH, Ad), 36.5 (C, Ad), 36.8 (3 CH_2 , Ad), 38.6 (C, *t*-Bu), 39.2 (3 CH_2 , Ad), 63.5 ($CHNH$), 111.4 (C4a), 126.9 (CH, Ph), 127.6 (2CH, Ph), 128.3 (2CH, Ph), 139.5 (C, Ph), 151.0 (C, Pyr), 153.2 (C, Pyr), 154.6 (C, Pyr); HRMS (ESI⁺, m/z): calc. for $C_{26}H_{33}N_3O$ [M+H] 404.2696, found 404.2696.

***N*-[1-Adamantyl(phenyl)methyl]-2-*tert*-butyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7z).**

Obtained as yellowish oil (56 mg, 25%); R_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.3); δ_H (400 MHz, $CDCl_3$): 1.42 (9H, s, 3 CH_3), 1.49 (3H, br d, $^2J_{HH}$ ca. 12, 3 CH_2 , Ad), 1.60 (3H, br d, $^2J_{HH}$ ca. 12, 3 CH_2 , Ad), 1.68–1.73 (6H, m, 3 CH_2 , Ad), 1.79–1.86 (4H, m, 2 CH_2 , cy-Hex), 2.00 (3H, br s, 3CH, Ad), 2.39–2.46 (2H, m, CH_2 , cy-Hex), 2.84–2.90 (2H, m, CH_2 , cy-Hex), 4.86 (1H, d, $^3J_{HH}$ 8.3, $CHNH$), 5.10 (1H, br d, $^3J_{HH}$ 8.3, NH), 7.16–7.19 (2H, m, 2CH, Ph), 7.21–7.31 (3H, m, 3CH, Ph); δ_C (101 MHz, $CDCl_3$): 20.9 (CH_2 , cy-Hex), 21.2 (CH_2 , cy-Hex), 22.1 (CH_2 , cy-Hex), 24.6 (CH_2 , cy-Hex), 26.8 (3 CH_3), 28.3 (3CH, Ad), 36.3 (C, Ad), 36.8 (3 CH_2 , Ad), 39.3 (3 CH_2 , Ad), 64.1 (CH), 111.6 (C4a), 126.8 (CH, Ph), 127.5 (2CH, Ph), 128.4 (2CH, Ph), 139.7 (C, Ph), 150.1 (C, Pyr), 154.9 (C, Pyr), 160.7 (C, Pyr); HRMS (ESI⁺, m/z): calc. for $C_{26}H_{39}N_3O$ [M+H] 446.3166, found 446.3162.

4-[4-(2-Adamantyl)piperazin-1-yl]-2-methyl-5,6,7,8-tetrahydroquinazoline 1-oxide (7aa).

Obtained as white solid (56 mg, 29%); mp 118–120°C (from $CHCl_3$); R_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.3); δ_H (400 MHz, $CDCl_3$): 1.37 (2H, br d, $^2J_{HH}$ ca. 12, CH_2 , Ad), 1.60–1.72 (6H, m, 2 CH_2 , Ad + CH_2 , cy-Hex), 1.77 (1H, br.s, CH, Ad), 1.79–1.90 (5H, m, CH_2 , Ad +




CH, Ad + CH₂, cy-Hex), 1.99–2.10 (5H, m, 2CH₂, Ad + 3CH, Ad), 2.46–2.57 (6H, m, 2CH₂N + CH₂, cy-Hex), 2.61 (3H, s, CH₃), 2.91 (2H, t, ³J_{HH} 6.6, CH₂, cy-Hex), 3.24–3.33 (4H, m, 2CH₂N); δ_C (101 MHz, CDCl₃): 19.9 (CH₃), 21.4 (CH₂, cy-Hex), 21.7 (CH₂, cy-Hex), 25.4 (CH₂, cy-Hex), 26.2 (CH₂, cy-Hex), 27.3 (CH, Ad), 27.5 (CH, Ad), 28.9 (2CH, Ad), 31.3 (2CH₂, Ad), 37.2 (2CH₂, Ad), 37.7 (CH₂, Ad), 48.8 (2CH₂N), 49.4 (2CH₂N), 67.6 (CHN, Ad), 118.8 (C4a), 154.0 (C, Pyr), 154.97 (C, Pyr), 155.01 (C, Pyr); HRMS (ESI⁺, m/z): calc. for C₂₃H₃₄N₄O [M+H] 383.2805, found 383.2800.

4-[4-(2-Adamantyl)piperazin-1-yl]-2-tert-butyl-5,6,7,8-tetrahydroquinazoline 1-oxide (7ab).




Obtained as white solid (108 mg, 51%); mp 75–78°C (from CHCl₃); R_f 0.1 (petroleum ether:EtOAc:MeOH 3:1:0.3); δ_H (400 MHz, CDCl₃): 1.40 (2H, br d, ²J_{HH} ca. 12, CH₂, Ad), 1.50 (9H, s, 3CH₃), 1.60–1.72 (6H, m, 2CH₂, Ad + CH₂, cy-Hex), 1.78 (1H, br s, CH, Ad), 1.80–1.89 (5H, m, CH₂, Ad + CH, Ad + CH₂, cy-Hex), 2.03–2.12 (5H, m, 2CH₂, Ad + 3CH, Ad), 2.48–2.57 (6H, m, 2CH₂N + CH₂, cy-Hex), 2.90 (2H, t, ³J_{HH} 6.6, CH₂, cy-Hex), 3.27–3.35 (4H, m, 2CH₂N); δ_C (101 MHz, CDCl₃): 21.60 (CH₂, cy-Hex), 21.64 (CH₂, cy-Hex), 25.5 (CH₂, cy-Hex), 26.3 (CH₂, cy-Hex), 26.7 (3CH₃), 27.3 (CH, Ad), 27.5 (CH, Ad), 28.9 (2CH, Ad), 31.3 (2CH₂, Ad), 37.2 (2CH₂, Ad), 37.7 (CH₂, Ad), 38.7 (C, *t*-Bu), 48.8 (2CH₂N), 49.4 (2CH₂N), 67.7 (CHN, Ad), 118.5 (C4a), 154.1 (C4, Pyr), 156.7 (C8a, Pyr), 160.1 (C2, Pyr); HRMS (ESI⁺, m/z): calc. for C₂₃H₃₄N₄O [M+H] 425.3275, found 425.3265.

4-Ethoxy-2-methyl-5,6,7,8-tetrahydroquinazoline 1-oxide (8). Obtained as admixture in synthesis of **7g** (30% according to ¹H NMR spectra of reaction mixture), **7j** (15%), **7n** (50%), **7p** (10%), **7r** (10%). For comparison **8** was obtained in the same conditions but without addition of amine **6** into the reaction mixture and isolated via column chromatography (SiO₂) as yellowish oil (45 mg, 43%), R_f 0.15 (petroleum ether:EtOAc:MeOH 3:1:0.1); δ_H (400 MHz, CDCl₃): 1.36 (3H, t, ³J_{HH} 7.0, CH₃, Et), 1.65–1.75 (2H, m, 2CH₂), 1.78–1.87 (2H, m, 2CH₂), 2.53 2H, (br.t, ³J_{HH} 6.2, CH₂), 2.63 (s, 3H, CH₃), 2.89 (2H, br.t, ³J_{HH} 6.3, CH₂), 4.37 (2H, q, ³J_{HH} 7.0, CH₂, Et); δ_C (101 MHz, CDCl₃): 14.4 (CH₃, Et), 19.8 (CH₂), 20.6 (CH₃), 21.1 (CH₂), 21.7 (CH₂), 24.8 (CH₂), 62.7 (CH₂, Et), 116.6 (C4a), 154.1 (C2), 156.1 (C8a), 156.7 (C4). HRMS (ESI⁺, m/z): calc. for C₁₁H₁₆N₂O₂ [M+H] 209.1285, found 209.1290.




N-Butyl-2-methyl-5,6,7,8-tetrahydroquinazoline-4-amine 1-oxide (7a)






N-Benzyl-2-methyl-5,6,7,8-tetrahydroquinazoline-4-amine 1-oxide (7b)






N-Benzyl-2-tert-butyl-5,6,7,8-tetrahydroquinazoline-4-amine 1-oxide (7c)






N-(4-Methoxybenzyl)-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7d)







2-Methoxy-5-[[2-methyl-1-oxido-5,6,7,8-tetrahydroquinazolin-4-yl)amino]methyl]phenol (7e)






2-Methyl-4-morpholin-4-yl-5,6,7,8-tetrahydroquinazoline 1-oxide (7f)





2-Methyl-4-morpholin-4-yl-5,6,7,8-tetrahydroquinazoline (7g)






4-Morpholin-4-yl-2-tert-butyl-5,6,7,8-tetrahydroquinazoline 1-oxide (7h)






4-Morpholin-4-yl-2-tert-butyl-5,6,7,8-tetrahydroquinazoline 1-oxide (7h)






2-Methyl-4-piperazin-1-yl-5,6,7,8-tetrahydroquinazoline 1-oxide (7i)






2-Methyl-4-piperazin-1-yl-5,6,7,8-tetrahydroquinazoline (7j) hydrochloride






4-Piperazin-1-yl-2-tert-butyl-5,6,7,8-tetrahydroquinazoline 1-oxide (7k)






2-Methyl-N-phenyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7I)






N-Phenyl-2-tert-butyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7m)






2-Methyl-N-(4-methylphenyl)-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7n)





2-[(2-Methyl-1-oxido-5,6,7,8-tetrahydroquinazolin-4-yl)amino]phenol (7o)






N-(1-Adamantylmethyl)-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7p)



N-(1-Adamantylmethyl)-2-tert-butyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7q)






N-[1-(1-Adamanty)ethyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7r)






N-[1-(1-Adamantyl)ethyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7r)




apt





N-[2-(1-Adamanty)ethyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7s)







N-[2-(1-Adamantyl)ethyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7s)



N-[2-(1-Adamanty)ethyl]-2-ethyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7t)






N-[2-(1-Adamantyl)ethyl]-2-tert-butyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7u)






N-[2-(1-Adamanty)ethyl]-2-tert-butyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7u)





apt






N-[2-(2-Adamanty)ethyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7v)






N-[2-(2-Adamantyl)ethyl]-2-tert-butyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7w)







N-[2-(1-Adamantyloxy)ethyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7x)






N-[1-adamantyl(phenyl)methyl]-2-methyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7y)




N-[1-Adamantyl(phenyl)methyl]-tert-butyl-5,6,7,8-tetrahydroquinazolin-4-amine 1-oxide (7z)




4-[4-(2-Adamantyl)piperazin-1-yl]-2-methyl-5,6,7,8-tetrahydroquinazoline 1-oxide (7aa)




4-[4-(2-Adamantyl)piperazin-1-yl]-2-methyl-5,6,7,8-tetrahydroquinazoline 1-oxide (7aa)






COSY H-H




HMQC




4-[4-(2-Adamantyl)piperazin-1-yl]-2-*tert*-butyl-5,6,7,8-tetrahydroquinazoline 1-oxide (5ab)





4-[4-(2-Adamantyl)piperazin-1-yl]-2-*tert*-butyl-5,6,7,8-tetrahydroquinazoline 1-oxide (7ab)






COSY H-H




4-[4-(2-Adamantyl)piperazin-1-yl]-2-tert-butyl-5,6,7,8-tetrahydroquinazoline 1-oxide (7ab)




N-Etoxy-2-methyl-5,6,7,8-tetrahydroquinazoline 1-oxide (8)



N-Etoxy-2-methyl-5,6,7,8-tetrahydroquinazoline 1-oxide (8)



HMBC






Figure S1. Time-of-addition assay results. Comparable with DMSO-control number of foci a) in second experiment (when cells were pre-incubated with the compounds for 1 h, and then virus was added to the cells) shows no impact of compound – cells interactions in inhibition of viral reproduction; b) in third experiment (when cells were pre-incubated with the virus for 1 h, then compounds were added to the cells) shows that compounds do not affect virus reproduction after virion incorporates the cell; c) results of standard PRT for compound **5y** are presented for comparison.